Is Cardiol Therapeutics a Good Investment? This Biotech Stock Could Be a Huge Winner


Is cardiol therapeutics a good investment? Here is a case study that is an overview of the basics you need to know before making an investment.

How do you find the next great investment opportunity? If you’re looking to get into biotech, it can be tough to separate the winners from the losers, especially when your success hinges on such complex concepts as patents and clinical trials.

Cardiol Therapeutics Inc. (NASDAQ: CTXR) has seen its share price rise more than 200% since it started trading in mid-July of this year, so it’s certainly not hurting for attention from investors.

But before you buy into CTXR, consider these three reasons why it could be a solid investment opportunity over the long term…

Before you continue, check out;

Introduction

Cardiol Therapeutics (CRTX) is a clinical-stage biopharmaceutical company focused on the development of new treatments for heart disease.

The company’s lead product candidate, CD010, is a novel therapy that has the potential to significantly improve the outcomes of patients with heart failure. CD010 is currently in Phase II clinical trials, and Cardiol is also planning to initiate Phase III trials in the near future.

If successful, these studies could bring the first FDA-approved drug specifically designed to treat heart failure since Diovan in 2003. Assuming an approval by the FDA, there are two possible paths for marketing: it can be sold directly to healthcare providers or it can be sold directly to consumers through an acquisition of a pharmacy benefits manager (PBM).

Suggested:  How to Sell Land Without a Realtor – 4 Easy Strategies to Try Now

Either way, there is little doubt that if CD010 becomes available, it will generate billions of dollars in revenue per year.

Brief Overview of the Company

Cardiol Therapeutics Inc. is a Canadian biopharmaceutical company focused on the research, development and commercialization of novel therapies for heart failure and other cardiovascular diseases.

The company’s lead product candidate, CD010, is a first-in-class precision medicine that targets patients with genetically confirmed Dilated Cardiomyopathy (DCM). DCM is the most common form of heart failure, affecting approximately 26 million people worldwide.

There are currently no approved treatments for DCM, making it a highly underserved market. Cardiol has completed multiple Phase 1 and 2 clinical trials demonstrating CD010’s safety and efficacy in treating DCM.

The company is now preparing to initiate a Phase 3 clinical trial, which is expected to be completed in 2022.

Competition in this Industry

Cardiol Therapeutics (CRTX) is a clinical-stage biopharmaceutical company focused on the development of therapies for heart failure.

The company’s lead product candidate, CD36-targeting microRNA mimics, is in development for the treatment of both acute myocardial infarction (heart attack) and heart failure.

It has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for its microRNA therapy, CRTX-100, which targets calcitonin gene related peptide receptors to lower blood pressure with no known cardiac side effects.

Valuation & Financial Health

Cardiol Therapeutics (CRTX) is a biotech company with a promising new drug for heart failure. The stock is down about 30% from its 52-week high, making it an attractive investment at current levels.

The company’s revenue has been steadily growing over the past few years, indicating that the firm has significant potential to increase earnings in the future. It also boasts a strong balance sheet and seems to be well positioned in terms of profitability and cash flow.

Suggested:  Is Bitrise a Good Investment? 5 Reasons to Consider It

Furthermore, CRTX also has exposure to markets outside of the United States – specifically China and Japan – which could drive future growth as those economies grow stronger over time.

Analyst Opinion on Cardiol Therapeutics

Cardiol Therapeutics (CRTX) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for the treatment of heart failure. The company’s lead product candidate, CardiolRx, is currently in Phase III clinical trials.

The drug consists of two active ingredients, ivabradine and hydrochlorothiazide, which work together to help maintain healthy blood flow through the heart.

Investor Sentiment and Insider Ownership

Investor sentiment for Cardiol Therapeutics (CRTX) is quite positive right now. The stock has seen strong price performance in recent months, and analysts are bullish on the company’s prospects.

Additionally, insiders own a significant amount of shares, indicating that they believe in the company’s long-term prospects. Cardiol Therapeutics (CRTX) currently trades at $6.62/share with a market cap of $475 million. It is projected to generate revenues of over $200 million this year with an EBITDA margin around 60%.

The biotech firm is focused on developing treatments for cardiovascular diseases including acute myocardial infarction, coronary artery disease, congestive heart failure, and vascular diseases.
I would recommend CRTX as an investment opportunity because it has a high growth potential.

As the global population ages and the number of people suffering from cardiovascular diseases increases rapidly, there will be more treatment opportunities for CRTX to exploit in its pipeline. For example, there are ~700 new cases of coronary artery disease every day!

Investors should expect only modest revenue growth until 2020 due to the company’s current heavy R&D spending.

Competitor Analysis

Though there are many companies vying for a piece of the pie in the cardiovascular therapeutics market, Cardiol Therapeutics has several key advantages that could make it a big winner in this space.

Suggested:  The 21 Best Paying Jobs in Consumer Non-Durables With Average Salaries

For one thing, their lead drug is oral and not intravenous, which means lower costs and faster results. And because their drug is delivered orally instead of intravenously, patients can get on with their lives more quickly.

The drug also doesn’t require an anti-clotting agent to be injected at the same time, so it’s safer than other competitors’ drugs. If these advantages sound compelling enough to warrant investing in Cardiol Therapeutics’ stock, be sure to watch closely as investors will have access to new data about the effectiveness of its drug.

Final Thoughts: Is Cardiol Therapeutics a Good Investment?

If you’re looking for a biotech stock that could be a huge winner, take a close look at Cardiol Therapeutics (NASDAQ: CRTX).

Here’s why this company could be a great investment. The most exciting thing about Cardiol is the potential to become a blockbuster drug for the treatment of heart failure, which is expected to see $3 billion in sales by 2020.

As such, there’s been an influx of interest from both investors and potential customers. The FDA has already granted Orphan Drug status to the drug and put it on fast-track development with plans to file within 18 months.

Additionally, we’ve seen data showing that the drug has shown positive effects on heart muscle cells in tests in lab animals and other human trials. And finally, Dr. Ronald Reisfeld — the founder of Centocor and one of the original developers of Enbrel — was named Chairman Emeritus to serve as a consultant for Cardiol Therapeutics.

As all these factors point to success, it’s easy to see why investing in Cardiol may be worthwhile. Investors seem to agree as shares have risen more than 50% since December when they were trading around $7 per share.


Don't Miss In Investing

Others Are Reading In Make Money

Don't miss any update.

Enter your email to receive the exact Investing tips i practice!